NLS Pharmaceutics AG ( NLSP) Stock. Should you Buy or Sell? $ 0.89
0.05 (5.64 %)
NLS Pharmaceutics AG Analysis
Updated on 10-09-2022| Symbol | NLSP |
| Price | $0.89 |
| Beta | 0.000 |
| Volume Avg. | $428.08 thousand |
| Market Cap | $17.35 M |
| 52 Week Range | $0.33 - $2.83 |
NLS Pharmaceutics AG opened the day at $0.89 which is +'5.64 % on yesterday's close. NLS Pharmaceutics AG has a 52 week high of $2.83 and 52 week low of $0.33, which is a difference of $2.5. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $17.35 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NLS Pharmaceutics AG for $17.35 M, it would take 15 years to get your money back. NLS Pharmaceutics AG are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
NLS Pharmaceutics AG Stock Forecast - Is NLS Pharmaceutics AG a Buy or Sell?
| DCF Score | ||
| ROE Score | ||
| ROA Score | ||
| DE Score | ||
| PE Score | ||
| PB Score | ||
| Overall Recommendation |
Growth and Value
| PE Ratio | -1.774 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing NLS Pharmaceutics AG
| Price Book Value Ratio | 17.323 | Price To Book Ratio | 17.323 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -1.774 |
How liquid is NLS Pharmaceutics AG
| Current Ratio | 2.381 |
| Quick Ratio | 2.276 |
Debt
| Debt Ratio | 0.906 | Debt Equity Ratio | 9.628 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about NLS Pharmaceutics AG
Penny stocks to add to your watch list this week. The post 4 Hot Penny Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Here's what you need to know about buying penny stocks on July 22nd The post What Know About Buying Penny Stocks on July 22nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol ER), in narcolepsy. For excessive daytime sleepiness (EDS), the trial's primary endpoint, patients on Mazindol ER exhibited a.
NLS Pharmaceutics Ltd NLSP shares are trading higher after the Company announced to present interim topline data from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), for narcolepsy at World Sleep Congress 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90% of patients completing the trial have opted into the Open Label Extension study ZURICH, SWITZERLAND / ACCESSWIRE / February 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it will present interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), for the treatment of narcolepsy at this year's World Sleep Congress (World Sleep 2022), taking place in Rome, Italy March 11-16, 2022.
About NLS Pharmaceutics AG
Description :
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
